Year-end Report January-December 2022
The strong growth in the core business during the fourth quarter continues in the beginning of 2023 October-December 2022 · Net sales totaled SEK 25,741 (42,060) thousand. Organic growth adjusted for license revenue from Selecta Biosciences in 2021 is 38% and when also adjusted for currency effect 21%. Net sales including license revenue from Selecta Biosciences decreased by -39% and adjusted for currency effect -48%. · Gross profit totaled SEK 23,031 (39,024) thousand. · Operating profit before depreciation and amortization (EBITDA) totaled SEK -5,915 (23,361) thousand.